Efficacy and Safety of Crisugabalin for Inadequately Controlled Diabetic Peripheral Neuropathic Pain: A Randomized, Active‐Controlled, Phase 2 Trial
Diabetes, Obesity and Metabolism · 2026-12 · 28 (12) · 11946-11954
DOI: 10.1111/dom.71401 ↗At a glance
Randomisierte kontrollierte Studie in Diabetes, Obesity and Metabolism, published online on 2026-10-02. Written by Yaming Li and 11 co-authors. Institution: Shaanxi Key Laboratory of Natural Products & Chemical Biology, College of Chemistry & Pharmacy, Northwest A&F University, Xianyang, Shaanxi Province,…. Major MEDLINE topics: Diabetic Neuropathies, Analgesics, gamma-Aminobutyric Acid, Neuralgia. Cited 1 times so far (Crossref); 43 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Haisco Pharmaceutical Group Co., Ltd.
Abstract (original language)
Aims
Crisugabalin (HSK16149), a selective γ‐aminobutyric acid (GABA) analog, has shown preliminary efficacy in controlling diabetic peripheral neuropathic pain (DPNP), but efficacy in patients with inadequate response to prior pregabalin treatment remains unknown. Materials and Methods This multicentre randomized controlled trial was conducted from April 18, 2024 to July 18, 2024. Adults patients with DPNP and inadequate response to pregabalin were randomized at a 1:1 ratio to receive crisugabalin (40 mg/day) or pregabalin (300 mg/day) for 4 weeks. The primary endpoint was the mean change of SF‐MPQ pain score from baseline to 4 weeks of treatment.
Results
Ninety‐three patients were randomized: 47 and 46 in the crisugabalin and pregabalin groups, respectively. The efficacy analysis included 90 patients (mean age, 58.9 years; 49 men). The least square mean (LSM) difference in the mean change of SF‐MPQ pain score was −7.2 (95% CI: −12.4, −2.0; ANCOVA p = 0.007) between the two groups. The rate of treatment‐emergent adverse events was 29.5% (13/44) and 47.8% (22/46) in the crisugabalin and pregabalin groups, respectively.
Conclusions
Treatment with crisugabalin 40 mg/day resulted in greater pain reduction in comparison to pregabalin 300 mg/day over a period of 4 weeks in DPNP patients with inadequate response to prior pregabalin treatment.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Shaanxi Key Laboratory of Natural Products & Chemical Biology, College of Chemistry & Pharmacy, Northwest A&F University, Xianyang, Shaanxi Province, China.
- Department of Endocrinology, Kaifeng Hospital of Traditional Chinese Medicine, Kaifeng, Henan Province, China.
- Department of Endocrinology, Yongzhou Central Hospital, Yongzhou, Hunan Province, China.
- Department of Endocrinology, Cangzhou Integrated Traditional Chinese and Western Medicine Hospital, Cangzhou, Hebei Province, China.
- Department of Endocrinology, Shaoyang Central Hospital, Shaoyang, Hunan Province, China.
- Department of Endocrinology, Nanyang Central Hospital, Nanyang, Henan Province, China.
ORCID profiles: Jinyou Duan
Funding
- Haisco Pharmaceutical Group Co., Ltd
Cite
APA
Li, Y., Zhang, F., Liu, W., Su, X., Zhou, B., Xu, N., Shang, J., Fang, C., Fu, L., Li, F., Zheng, C., & Duan, J. (2026). Efficacy and Safety of Crisugabalin for Inadequately Controlled Diabetic Peripheral Neuropathic Pain: A Randomized, Active‐Controlled, Phase 2 Trial. Diabetes, Obesity and Metabolism, 28(12), 11946-11954. https://doi.org/10.1111/dom.71401
Vancouver
Li Y, Zhang F, Liu W, Su X, Zhou B, Xu N, et al. Efficacy and Safety of Crisugabalin for Inadequately Controlled Diabetic Peripheral Neuropathic Pain: A Randomized, Active‐Controlled, Phase 2 Trial. Diabetes, Obesity and Metabolism. 2026;28(12):11946-11954. doi:10.1111/dom.71401
BibTeX
@article{Li2026,
author = {Li, Yaming and Zhang, Fang and Liu, Wei and Su, Xiuhai and Zhou, Bin and Xu, Na and Shang, Junjie and Fang, Chen and Fu, Liujun and Li, Fangqiong and Zheng, Chao and Duan, Jinyou},
title = {Efficacy and Safety of Crisugabalin for Inadequately Controlled Diabetic Peripheral Neuropathic Pain: A Randomized, Active‐Controlled, Phase 2 Trial},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {12},
pages = {11946--11954},
doi = {10.1111/dom.71401}
}
EUVIMED